|
Impact of unbalanced karyotypes at diagnosis on prognosis of CML. |
|
|
Research Funding - Bristol-Myers Squibb; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Munich Leukemia Laboratory |
Leadership - Munich Leukemia Laboratory |
Stock and Other Ownership Interests - Munich Leukemia Laboratory |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer |
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Cerus; MSD; Novartis; Takeda |
Consulting or Advisory Role - MSD |
Travel, Accommodations, Expenses - Amgen; Gilead Sciences; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer |
Consulting or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer |
|
|
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb; Novartis |
|
|
No Relationships to Disclose |